verapamil has been researched along with Kidney Failure in 7 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacokinetics and antithrombotic effects of the Factor Xa inhibitor rivaroxaban were studied in subjects with mild renal insufficiency concurrently taking the P-glycoprotein and moderate CYP3A inhibitor verapamil, a drug commonly administered to patients with hypertension, ischemic heart disease, or atrial fibrillation." | 9.27 | Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. ( Chow, CR; Greenblatt, DJ; Harmatz, JS; Nicholson, WT; Patel, M; Rubino, CM, 2018) |
| "We examined the effect of a calcium channel blocker (verapamil) on renal functions and the abundance of apoptotic (p53, Fas, proliferating cell nuclear antigen [PCNA]) markers 1 week after Unilateral Ureteral Obstruction (UUO)." | 7.74 | Verapamil prevents the apoptotic and hemodynamic changes in response to unilateral ureteral obstruction. ( Celik, S; Erbagci, A; Erturhan, S; Topcu, SO; Ucak, R; Yagci, F, 2008) |
| "It is indicated for the treatment of hypertension in patients who require more than one agent to achieve blood pressure (BP) targets." | 6.43 | Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005) |
| "Pharmacokinetics and antithrombotic effects of the Factor Xa inhibitor rivaroxaban were studied in subjects with mild renal insufficiency concurrently taking the P-glycoprotein and moderate CYP3A inhibitor verapamil, a drug commonly administered to patients with hypertension, ischemic heart disease, or atrial fibrillation." | 5.27 | Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. ( Chow, CR; Greenblatt, DJ; Harmatz, JS; Nicholson, WT; Patel, M; Rubino, CM, 2018) |
| " To quantify the impacts of concomitant verapamil administration and renal impairment on rivaroxaban pharmacokinetics, a minimal physiologically based pharmacokinetic model system was developed and used to evaluate potential increases in rivaroxaban exposure and the consequent increase in risk of major bleeding." | 5.27 | Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects. ( Chow, CR; Ismail, M; Lee, VH; Rubino, CM, 2018) |
| "We examined the effect of a calcium channel blocker (verapamil) on renal functions and the abundance of apoptotic (p53, Fas, proliferating cell nuclear antigen [PCNA]) markers 1 week after Unilateral Ureteral Obstruction (UUO)." | 3.74 | Verapamil prevents the apoptotic and hemodynamic changes in response to unilateral ureteral obstruction. ( Celik, S; Erbagci, A; Erturhan, S; Topcu, SO; Ucak, R; Yagci, F, 2008) |
| "It is indicated for the treatment of hypertension in patients who require more than one agent to achieve blood pressure (BP) targets." | 2.43 | Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005) |
| " The validated lesinurad plasma quantification method was successfully applied for the pharmacokinetic evaluations to support the clinical studies in renal impaired patients." | 1.51 | The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS. ( Nguyen, M; Sun, L; Wilson, DM; Yeh, LT; Zhou, D, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, D | 1 |
| Sun, L | 1 |
| Nguyen, M | 1 |
| Yeh, LT | 1 |
| Wilson, DM | 1 |
| Greenblatt, DJ | 1 |
| Patel, M | 1 |
| Harmatz, JS | 1 |
| Nicholson, WT | 1 |
| Rubino, CM | 2 |
| Chow, CR | 2 |
| Ismail, M | 1 |
| Lee, VH | 1 |
| Reynolds, NA | 1 |
| Wagstaff, AJ | 1 |
| Keam, SJ | 1 |
| Topcu, SO | 1 |
| Celik, S | 1 |
| Erturhan, S | 1 |
| Erbagci, A | 1 |
| Yagci, F | 1 |
| Ucak, R | 1 |
| Daroca Pérez, R | 1 |
| Alfaro Olea, A | 1 |
| San Román Lazcano, FJ | 1 |
| Jiménez Santolaya, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for verapamil and Kidney Failure
| Article | Year |
|---|---|
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug C | 2005 |
2 trials available for verapamil and Kidney Failure
| Article | Year |
|---|---|
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Topics: Adult; Aged; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Female; Hem | 2018 |
Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.
Topics: Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Midd | 2018 |
4 other studies available for verapamil and Kidney Failure
| Article | Year |
|---|---|
The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS.
Topics: Allopurinol; Calibration; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Hepatic In | 2019 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Verapamil prevents the apoptotic and hemodynamic changes in response to unilateral ureteral obstruction.
Topics: Animals; Apoptosis; Calcium Channel Blockers; fas Receptor; Hemodynamics; Kidney; Kidney Tubules; Ma | 2008 |
[Poisoning by delayed-release verapamil in renal insufficiency patients].
Topics: Aged; Aged, 80 and over; Delayed-Action Preparations; Female; Humans; Hypertension; Poisoning; Renal | 1993 |